Dupilumab development program Dupilumab is being jointly developed by Sanofi and ... referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron ...

Regeneron Pharmaceuticals and Sanofi have announced more positive results for their novel drug dupilumab in the allergic inflammatory arena. Their phase IIa proof-of-concept study of dupilumab ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi under ... or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products ...

Sanofi and Regeneron's Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a rare and highly debilitating skin disease. The EMA's human ...

In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad ... All trademarks mentioned in this press release are the property of the Sanofi group ...

and Sanofi today presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent ® (dupilumab) in adults with moderate-to-severe bullous ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi under ... or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results ...